These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34519187)

  • 1. Latent Tuberculosis Infection Screening and Treatment in Congregate Settings (TB FREE COREA): Demographic Profiles of Interferon-Gamma Release Assay Cohort.
    Kim HW; Min J; Choi JY; Shin AY; Myong JP; Lee Y; Yim HW; Jeong H; Bae S; Shim E; In H; Chun C; Kim G; Kang JY; Lee SS; Park JS; Kim JS
    J Korean Med Sci; 2021 Sep; 36(36):e246. PubMed ID: 34519187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal.
    Sousa S; Rocha D; Silva JC; Ribeiro AI; Gonçalves G; Almeida Á; Correia AM; Duarte R; Carvalho C
    Pulmonology; 2021; 27(6):493-499. PubMed ID: 34053903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil.
    Costa AG; Carvalho BKS; Araújo-Pereira M; Ibiapina HNS; Spener-Gomes R; Souza AB; Gomes-Silva A; Andrade AMS; Silva EC; Arriaga MB; Benjamin A; Rocha MS; Moreira ASR; Oliveira JG; Figueiredo MC; Turner MM; Durovni B; Cavalcante S; Kritski AL; Rolla VC; Sterling TR; Andrade BB; Cordeiro-Santos M;
    Microbiol Spectr; 2021 Dec; 9(3):e0116321. PubMed ID: 34851140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
    Haukaas FS; Arnesen TM; Winje BA; Aas E
    Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Mycobacterium tuberculosis infection as measured by the QuantiFERON-TB Gold assay and ESAT-6 free IGRA among adolescents in Mwanza, Tanzania.
    Jeremiah K; Lyimo E; Ritz C; PrayGod G; Rutkowski KT; Korsholm KS; Ruhwald M; Tait D; Grewal HMS; Faurholt-Jepsen D
    PLoS One; 2021; 16(6):e0252808. PubMed ID: 34097715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Tuberculosis Among Immigrants in Korea Who Participated in a Latent Tuberculosis Infection Screening Program.
    Lee YJ; Min J; Myong JP; Lee YH; Park YJ; Kim Y; Kim G; Park G; Lee SS; Park JS; Kim JS; Kim HW
    J Korean Med Sci; 2024 Jul; 39(28):e207. PubMed ID: 39048302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of latent tuberculosis infection among participants of the national LTBI screening program in South Korea - A problem of low coverage rate with current LTBI strategy.
    Kim HW; Min J; Choi JY; Shin AY; Myong JP; Lee Y; Yim HW; Jeong H; Bae S; Choi H; In H; Park A; Jang M; Koo HK; Lee SS; Park JS; Kim JS
    Front Public Health; 2022; 10():1066269. PubMed ID: 36743163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea.
    Min J; Kim HW; Stagg HR; Lipman M; Rangaka MX; Myong JP; Yim HW; Lim JU; Lee Y; Koo HK; Lee SS; Park JS; Cho KS; Kim JS
    BMJ Open; 2020 Feb; 10(2):e034098. PubMed ID: 32075836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of an interferon-gamma release assay to screen for pediatric latent tuberculosis infection in the eastern region of the Emirate of Abu Dhabi.
    Al Mekaini LA; Al Jabri ON; Narchi H; Kamal SM; Mabrook A; Al Kuwaiti MM; Sheek-Hussein MM; Souid AK; Alsuwaidi AR
    Int J Infect Dis; 2014 Jun; 23():4-7. PubMed ID: 24657274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation and treatment of latent tuberculosis infection among healthcare workers in Korea: A multicentre cohort analysis.
    Han SS; Lee SJ; Yim JJ; Song JH; Lee EH; Kang YA
    PLoS One; 2019; 14(9):e0222810. PubMed ID: 31536577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.
    Greenaway C; Pareek M; Abou Chakra CN; Walji M; Makarenko I; Alabdulkarim B; Hogan C; McConnell T; Scarfo B; Christensen R; Tran A; Rowbotham N; van der Werf MJ; Noori T; Pottie K; Matteelli A; Zenner D; Morton RL
    Euro Surveill; 2018 Apr; 23(14):. PubMed ID: 29637889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study.
    Klautau GB; da Mota NVF; Salles MJC; Burattini MN; Rodrigues DS
    BMC Infect Dis; 2018 Nov; 18(1):585. PubMed ID: 30453903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA.
    Jeong DH; Kang J; Jung YJ; Yoo B; Lee CK; Kim YG; Hong S; Shim TS; Jo KW
    PLoS One; 2018; 13(7):e0198756. PubMed ID: 29975703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study.
    Abubakar I; Lalvani A; Southern J; Sitch A; Jackson C; Onyimadu O; Lipman M; Deeks JJ; Griffiths C; Bothamley G; Kon OM; Hayward A; Lord J; Drobniewski F
    Health Technol Assess; 2018 Oct; 22(56):1-96. PubMed ID: 30334521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased annual risk of tuberculosis infection in South Korean healthcare workers using interferon-gamma release assay between 1986 and 2005.
    Lee EH; Son NH; Kwak SH; Choi JS; Kim MC; Seol CH; Kim SR; Park BH; Kang YA
    BMC Infect Dis; 2021 Nov; 21(1):1161. PubMed ID: 34784896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.
    Cao X; Guo T; Xin H; Du J; Yang C; Feng B; He Y; Shen L; Di Y; Li Z; Chen Y; Liang J; Jin Q; Wang L; Gao L
    Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):809-820. PubMed ID: 38383889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening.
    Lim RK; Talavlikar R; Chiazor O; Bietz J; Gardiner H; Fisher D
    BMC Infect Dis; 2021 Sep; 21(1):936. PubMed ID: 34503458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
    Palacios CF; Chowdhary V; Hao R; Danve A; Malinis M
    PLoS One; 2024; 19(7):e0306337. PubMed ID: 38959249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
    Cui X; Gao L; Cao B
    Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Close contact interferon-gamma response to the new PstS1
    de Araujo LS; de Bárbara Moreira da Silva Lins N; Leung JA; Mello FC; Saad MH
    BMC Res Notes; 2017 Jan; 10(1):59. PubMed ID: 28114976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.